- Down Syndrome Screening Risk Calculation Software Free
- Risk Calculation Formula
- Down Syndrome Risk Calculator
- Incidence and Etiology. The Roche solution for first trimester Down screening is based on performing a risk calculation using the risk assessment software SsdwLab6 using the two Elecsys biomarkers PAPP-A and free beta-hCG, combined with the NT measurement. These two Elecsys biomarkers are compliant with the FMF (Fetal Medicine Foundation) criteria.
- » Down Syndrome screening. The likelihood ratio of the test to calculate a new risk, which. It tests not just for Down syndrome but also for the most common.
Again, a computer program is used to give the risk of the baby having Down's syndrome, based on the blood test results, your age, the stage that you are at in your pregnancy, your weight, ethnicity and smoking status. The blood test used in Down's syndrome screening is also sometimes called serum screening.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (302K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
These references are in PubMed. This may not be the complete list of references from this article.
- Chamberlain G. ABC of antenatal care. Normal antenatal management. BMJ. 1991 Mar 30;302(6779):774–779.[PMC free article] [PubMed] [Google Scholar]
- Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, Palomaki GE, Canick JA. Maternal serum screening for Down's syndrome in early pregnancy. BMJ. 1988 Oct 8;297(6653):883–887.[PMC free article] [PubMed] [Google Scholar]
- Macri JN, Kasturi RV, Krantz DA, Cook EJ, Sunderji SG, Larsen JW. Maternal serum Down syndrome screening: unconjugated estriol is not useful. Am J Obstet Gynecol. 1990 Mar;162(3):672–673. [PubMed] [Google Scholar]
- Bartels I, Lindemann A. Maternal levels of pregnancy-specific beta 1-glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome. Hum Genet. 1988 Sep;80(1):46–48. [PubMed] [Google Scholar]
- O'Brien WF, Knuppel RA, Torres C, Sternlicht D. Potential prenatal predictions of Down syndrome: a statistical analysis. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 1):1796–1798. [PubMed] [Google Scholar]
- Cuckle HS, Wald NJ, Goodburn SF, Sneddon J, Amess JA, Dunn SC. Measurement of activity of urea resistant neutrophil alkaline phosphatase as an antenatal screening test for Down's syndrome. BMJ. 1990 Nov 3;301(6759):1024–1026.[PMC free article] [PubMed] [Google Scholar]
Associated Data
- Supplementary Materials
Nuchal translucency is the fluid present under the neck of still to be born babies. It can been seen using ultrasound between 11 weeks 2 days to 14 weeks 1 day of pregnancy. Babies with abnormalities are found to accumulate more NT fluid at the back of their neck during the first trimester. NT cannot be seen at the end of second trimester.
Nuchal translucency is the fluid present under the neck of still to be born babies. It can been seen using ultrasound between 11 weeks 2 days to 14 weeks 1 day of pregnancy. Babies with abnormalities are found to accumulate more NT fluid at the back of their neck during the first trimester. NT cannot be seen at the end of second trimester.
Example
Nuchal Translucency (NT)
If the crown rump length is 60 mm, then the Expected nuchal translucency is 1.61 mm, predicted gestational age is 12 weeks, 3 daysIf the measured NT is 2 mm for the CRL 60 mm, then Measured NT is 75 percentile for this CRL.
Find the expected Nuchal Translucency (NT) and Predicted Gestational Age using this Nuchal translucency calculator.